Advertisement

Therapeutic advances for the management of congenital adrenal hyperplasia

Published:August 13, 2022DOI:https://doi.org/10.1016/j.pedn.2022.07.018
      Over 150 years ago Luigi DeCrecchio first described what we now know as congenital adrenal hyperplasia (CAH). It took another 100 years for Dr. Lawson Wilkins and colleagues to develop effective cortisone treatment. CAH has been treated in much the same way since, but the advent of new pharmacotherapies seeks to revitalize the treatment of this complex disorder (
      • Mallappa A.
      • Merke D.P.
      Management challenges and therapeutic advances in congenital adrenal hyperplasia.
      ).
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      References

        • BridgeBio Pharma Inc
        BridgeBio pharma announces dosing of first patient in Phase 1/ 2 trial of investigational gene therapy for congenital adrenal hyperplasia (CAH). Globenewswire. Retrieved April 18, 2022, from.
        • Claahsen-van der Grinten H.L.
        • Speiser P.W.
        • Ahmed S.F.
        • Arlt W.
        • Auchus R.J.
        • Falhammar H.
        • Flück C.E.
        • Guasti L.
        • Huebner A.
        • Kortmann B.B.M.
        • Krone N.
        • Merke D.P.
        • Miller W.L.
        • Nordenström A.
        • Reisch N.
        • Sandberg D.E.
        • Stikkelbroeck N.M.M.L.
        • Touraine P.
        • Utari A.
        • White P.C.
        Congenital adrenal hyperplasia-current insights in pathophysiology, diagnostics, and management.
        Endocrine Reviews. 2022; 43: 91-159
        • ClinicalTrials.gov
        February 28.
        CAH clinical trials, Search Results2022 (Retrieved February 28, 2022, from)
        • Crossject
        Conformity of the first industrial transposition batch of Zeneo hydrocortisone.
        (Retrieved April 17, 2022, from)
        • Earnst D.
        Hydrocortisone rescue pen fast tracked for adrenal insufficiency.
        (MPR: Medical Professionals Reference. Retrieved on April 18, 2022, from)
        • Isidori A.M.
        • Arnaldi G.
        • Boscaro M.
        • Falorni A.
        • Giordano C.
        • Giordano R.
        • Pivonello R.
        • Pozza C.
        • Sbardella E.
        • Simeoli C.
        • Scaroni C.
        • Lenzi A.
        • Italian Society of Endocrinology
        Towards the tailoring of glucocorticoid replacement in adrenal insufficiency: The Italian society of endocrinology expert opinion.
        Journal of Endocrinological Investigation. 2020; 43: 683-696https://doi.org/10.1007/s40618-019-01146-y
        • Mallappa A.
        • Merke D.P.
        Management challenges and therapeutic advances in congenital adrenal hyperplasia.
        Nature Reviews. Endocrinology. 2022; https://doi.org/10.1038/s41574-022-00655-w
        • Mallappa A.
        • Nella A.A.
        • Sinaii N.
        • Rao H.
        • Gounden V.
        • Perritt A.F.
        • Kumar P.
        • Ling A.
        • Liu C.-Y.
        • Soldin S.J.
        • Merke D.P.
        Long-term use of continuous subcutaneous hydrocortisone infusion therapy in patients with congenital adrenal hyperplasia.
        Clinical Endocrinology. 2018; 89: 399-407https://doi.org/10.1111/cen.13813
        • Nordenström A.
        • Falhammar H.
        • Lajic S.
        Current and novel treatment strategies in children with congenital adrenal hyperplasia.
        Hormone Research in Pædiatrics. 2022; https://doi.org/10.1159/000522260